Aytu BioPharma (AYTU) Competitors

$2.19 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.19 0.00 (0.00%)

As of 05/22/2026 04:10 PM Eastern

AYTU vs. ICCC, CLNN, CUE, JATT, and ATRA

Should you buy Aytu BioPharma stock or one of its competitors? MarketBeat compares Aytu BioPharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aytu BioPharma include ImmuCell (ICCC), Clene (CLNN), Cue Biopharma (CUE), JATT Acquisition (JATT), and Atara Biotherapeutics (ATRA). These companies are all part of the "pharmaceutical products" industry.

How does Aytu BioPharma compare to ImmuCell?

Aytu BioPharma (NASDAQ:AYTU) and ImmuCell (NASDAQ:ICCC) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Aytu BioPharma has a beta of 0.28, suggesting that its stock price is 72% less volatile than the broader market. Comparatively, ImmuCell has a beta of 0.5, suggesting that its stock price is 50% less volatile than the broader market.

ImmuCell has lower revenue, but higher earnings than Aytu BioPharma. ImmuCell is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
ImmuCell	$27.64M	3.31	-$1.04M	-$0.06	N/A

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Aytu BioPharma's average media sentiment score of 0.22 beat ImmuCell's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ImmuCell	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ImmuCell has a net margin of -1.82% compared to Aytu BioPharma's net margin of -60.17%. ImmuCell's return on equity of -1.88% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
ImmuCell	-1.82%	-1.88%	-1.22%

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 13.5% of ImmuCell shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 5.7% of ImmuCell shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aytu BioPharma currently has a consensus price target of $9.33, indicating a potential upside of 326.18%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Aytu BioPharma is more favorable than ImmuCell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
ImmuCell	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

ImmuCell beats Aytu BioPharma on 8 of the 15 factors compared between the two stocks.

How does Aytu BioPharma compare to Clene?

Aytu BioPharma (NASDAQ:AYTU) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 23.3% of Clene shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 28.3% of Clene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Aytu BioPharma has higher revenue and earnings than Clene. Clene is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
Clene	$200K	428.13	-$26.17M	-$3.20	N/A

Aytu BioPharma currently has a consensus target price of $9.33, suggesting a potential upside of 326.18%. Clene has a consensus target price of $33.25, suggesting a potential upside of 396.27%. Given Clene's stronger consensus rating and higher possible upside, analysts plainly believe Clene is more favorable than Aytu BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Clene	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

In the previous week, Clene had 5 more articles in the media than Aytu BioPharma. MarketBeat recorded 6 mentions for Clene and 1 mentions for Aytu BioPharma. Clene's average media sentiment score of 0.67 beat Aytu BioPharma's score of 0.22 indicating that Clene is being referred to more favorably in the news media.

Company	Overall Sentiment
Aytu BioPharma	Neutral
Clene	Positive

Aytu BioPharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Clene has a beta of 0.89, suggesting that its share price is 11% less volatile than the broader market.

Aytu BioPharma has a net margin of -60.17% compared to Clene's net margin of -25,009.70%. Clene's return on equity of 0.00% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Clene	-25,009.70%	N/A	-137.98%

Summary

Clene beats Aytu BioPharma on 10 of the 16 factors compared between the two stocks.

How does Aytu BioPharma compare to Cue Biopharma?

Aytu BioPharma (NASDAQ:AYTU) and Cue Biopharma (NASDAQ:CUE) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Aytu BioPharma has a beta of 0.28, suggesting that its share price is 72% less volatile than the broader market. Comparatively, Cue Biopharma has a beta of 2.37, suggesting that its share price is 137% more volatile than the broader market.

Cue Biopharma has a net margin of -59.65% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Cue Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
Cue Biopharma	-59.65%	-98.30%	-53.69%

Aytu BioPharma currently has a consensus target price of $9.33, indicating a potential upside of 326.18%. Given Aytu BioPharma's stronger consensus rating and higher possible upside, analysts plainly believe Aytu BioPharma is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Aytu BioPharma has higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
Cue Biopharma	$27.47M	3.17	-$26.60M	-$5.58	N/A

33.5% of Aytu BioPharma shares are owned by institutional investors. Comparatively, 35.0% of Cue Biopharma shares are owned by institutional investors. 4.9% of Aytu BioPharma shares are owned by insiders. Comparatively, 1.8% of Cue Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Cue Biopharma had 1 more articles in the media than Aytu BioPharma. MarketBeat recorded 2 mentions for Cue Biopharma and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.22 beat Cue Biopharma's score of -0.12 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cue Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Aytu BioPharma beats Cue Biopharma on 11 of the 16 factors compared between the two stocks.

How does Aytu BioPharma compare to JATT Acquisition?

Aytu BioPharma (NASDAQ:AYTU) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, valuation, analyst recommendations, media sentiment, earnings, risk and institutional ownership.

Aytu BioPharma presently has a consensus target price of $9.33, suggesting a potential upside of 326.18%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, equities analysts clearly believe Aytu BioPharma is more favorable than JATT Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

JATT Acquisition has lower revenue, but higher earnings than Aytu BioPharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

In the previous week, Aytu BioPharma and Aytu BioPharma both had 1 articles in the media. Aytu BioPharma's average media sentiment score of 0.22 beat JATT Acquisition's score of 0.00 indicating that Aytu BioPharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aytu BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
JATT Acquisition	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

33.5% of Aytu BioPharma shares are held by institutional investors. Comparatively, 48.0% of JATT Acquisition shares are held by institutional investors. 4.9% of Aytu BioPharma shares are held by company insiders. Comparatively, 20.0% of JATT Acquisition shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

JATT Acquisition has a net margin of 0.00% compared to Aytu BioPharma's net margin of -60.17%. JATT Acquisition's return on equity of -49.58% beat Aytu BioPharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aytu BioPharma	-60.17%	-69.93%	-13.25%
JATT Acquisition	N/A	-49.58%	2.84%

Summary

JATT Acquisition beats Aytu BioPharma on 6 of the 11 factors compared between the two stocks.

How does Aytu BioPharma compare to Atara Biotherapeutics?

Atara Biotherapeutics (NASDAQ:ATRA) and Aytu BioPharma (NASDAQ:AYTU) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, dividends, valuation and earnings.

In the previous week, Atara Biotherapeutics had 20 more articles in the media than Aytu BioPharma. MarketBeat recorded 21 mentions for Atara Biotherapeutics and 1 mentions for Aytu BioPharma. Aytu BioPharma's average media sentiment score of 0.22 beat Atara Biotherapeutics' score of 0.15 indicating that Aytu BioPharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Atara Biotherapeutics	2 Very Positive mention(s)	1 Positive mention(s)	16 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Aytu BioPharma	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 33.5% of Aytu BioPharma shares are owned by institutional investors. 41.2% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 4.9% of Aytu BioPharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Atara Biotherapeutics has a net margin of -40.91% compared to Aytu BioPharma's net margin of -60.17%. Aytu BioPharma's return on equity of -69.93% beat Atara Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%
Aytu BioPharma	-60.17%	-69.93%	-13.25%

Atara Biotherapeutics currently has a consensus target price of $9.50, suggesting a potential downside of 3.06%. Aytu BioPharma has a consensus target price of $9.33, suggesting a potential upside of 326.18%. Given Aytu BioPharma's stronger consensus rating and higher probable upside, analysts plainly believe Aytu BioPharma is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aytu BioPharma	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Atara Biotherapeutics has a beta of -0.3, indicating that its stock price is 130% less volatile than the broader market. Comparatively, Aytu BioPharma has a beta of 0.28, indicating that its stock price is 72% less volatile than the broader market.

Atara Biotherapeutics has higher revenue and earnings than Aytu BioPharma. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Aytu BioPharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Atara Biotherapeutics	$120.77M	0.73	$32.69M	-$0.67	N/A
Aytu BioPharma	$66.38M	0.35	-$13.56M	-$4.58	N/A

Summary

Atara Biotherapeutics and Aytu BioPharma tied by winning 8 of the 16 factors compared between the two stocks.

Get Aytu BioPharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding AYTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

AYTU vs. The Competition

Export

Metric	Aytu BioPharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.51M	$3.37B	$6.46B	$12.34B
Dividend Yield	N/A	2.26%	2.76%	5.28%
P/E Ratio	-0.48	18.74	21.00	25.66
Price / Sales	0.35	323.98	558.19	86.31
Price / Cash	5.83	125.17	43.49	56.67
Price / Book	0.67	7.09	10.40	7.14
Net Income	-$13.56M	$24.45M	$3.57B	$335.98M
7 Day Performance	5.29%	6.38%	6.40%	4.11%
1 Month Performance	-13.10%	2.43%	3.55%	2.52%
1 Year Performance	11.73%	62.98%	34.13%	35.04%

Aytu BioPharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
AYTU Aytu BioPharma	2.3346 of 5 stars	$2.19 flat	$9.33 +326.2%	+11.7%	$23.51M	$66.38M	N/A	160
ICCC ImmuCell	0.4945 of 5 stars	$10.20 +2.9%	N/A	+55.2%	$89.65M	$27.64M	N/A	70
CLNN Clene	3.5876 of 5 stars	$6.38 -6.0%	$33.25 +421.2%	+182.7%	$86.76M	$200K	N/A	100	Gap Up
CUE Cue Biopharma	0.6683 of 5 stars	$20.30 -5.1%	N/A	-96.4%	$86.50M	$27.47M	N/A	60	Gap Down
JATT JATT Acquisition	N/A	$10.77 -1.6%	N/A	+994.7%	$85.45M	N/A	N/A	3	Quiet Period Expiration

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:AYTU) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aytu BioPharma (AYTU) Competitors

AYTU vs. ICCC, CLNN, CUE, JATT, and ATRA

How does Aytu BioPharma compare to ImmuCell?

Summary

How does Aytu BioPharma compare to Clene?

Summary

How does Aytu BioPharma compare to Cue Biopharma?

Summary

How does Aytu BioPharma compare to JATT Acquisition?

Summary

How does Aytu BioPharma compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Aytu BioPharma (AYTU) Competitors

AYTU vs. ICCC, CLNN, CUE, JATT, and ATRA

How does Aytu BioPharma compare to ImmuCell?

Which has more risk & volatility, AYTU or ICCC?

Which has better valuation and earnings, AYTU or ICCC?

Does the media refer more to AYTU or ICCC?

Is AYTU or ICCC more profitable?

Do insiders & institutionals believe in AYTU or ICCC?

Do analysts prefer AYTU or ICCC?

Summary

How does Aytu BioPharma compare to Clene?

Do insiders & institutionals hold more shares of AYTU or CLNN?

Which has stronger earnings & valuation, AYTU or CLNN?

Do analysts rate AYTU or CLNN?

Does the media prefer AYTU or CLNN?

Which has more volatility and risk, AYTU or CLNN?

Is AYTU or CLNN more profitable?

Summary

How does Aytu BioPharma compare to Cue Biopharma?

Which has more volatility & risk, AYTU or CUE?

Is AYTU or CUE more profitable?

Do analysts prefer AYTU or CUE?

Which has preferable valuation and earnings, AYTU or CUE?

Do insiders & institutionals have more ownership in AYTU or CUE?

Does the media refer more to AYTU or CUE?

Summary

How does Aytu BioPharma compare to JATT Acquisition?

Do analysts recommend AYTU or JATT?

Which has better earnings and valuation, AYTU or JATT?

Does the media favor AYTU or JATT?

Do institutionals and insiders have more ownership in AYTU or JATT?

Is AYTU or JATT more profitable?

Summary

How does Aytu BioPharma compare to Atara Biotherapeutics?

Does the media favor ATRA or AYTU?

Do insiders & institutionals hold more shares of ATRA or AYTU?

Is ATRA or AYTU more profitable?

Do analysts prefer ATRA or AYTU?

Which has more risk & volatility, ATRA or AYTU?

Which has stronger valuation and earnings, ATRA or AYTU?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

AYTU vs. The Competition

Aytu BioPharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools